These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25899762)

  • 21. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia.
    Hsueh PR; Hawkey PM
    Int J Antimicrob Agents; 2007 Aug; 30(2):129-33. PubMed ID: 17467246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
    Kaur R; Gautam V; Singhal L; Ray P
    J Antibiot (Tokyo); 2014 Aug; 67(8):603-4. PubMed ID: 24756027
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of resistance of aerobic gram-negative bacilli to broad-spectrum antibacterial agents: results of a multicentre study.
    Kresken M; Jansen A; Wiedemann B
    J Antimicrob Chemother; 1990 Jun; 25(6):1022-4. PubMed ID: 2115035
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011.
    Haeili M; Ghodousi A; Nomanpour B; Omrani M; Feizabadi MM
    J Infect Dev Ctries; 2013 Apr; 7(4):312-7. PubMed ID: 23592640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
    J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of the epidemiological situation and the resistance phenotype of pathogens isolated from patients in the intensive care unite of the Lodz Medical University Hospital No.1 in 2002-2006].
    Bartoszko-Tyczkowska A; Gaszyński W; Tyczkowska-Sieroń E
    Med Dosw Mikrobiol; 2008; 60(3):223-30. PubMed ID: 19143176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inducible clindamycin resistance among staphylococcus aureus isolates in a tertiary care hospital of Assam.
    Phukan C; Ahmed GU; Sarma PP
    Indian J Med Microbiol; 2015; 33(3):456-8. PubMed ID: 26068362
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK; Ying CM; Lee CC; Liu ZK
    Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A call to arms: the imperative for antimicrobial stewardship.
    Bartlett JG
    Clin Infect Dis; 2011 Aug; 53 Suppl 1():S4-7. PubMed ID: 21795727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin-tazobactam versus ciprofloxacin plus amoxicillin in the treatment of infective episodes after liver transplantation.
    Philpott-Howard J; Burroughs A; Fisher N; Hastings M; Kibbler C; Mutimer D; Patch D; Rolando N; Wade J; Wendon J; O'Grady J
    J Antimicrob Chemother; 2003 Dec; 52(6):993-1000. PubMed ID: 14585863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of six phenotypic methods for detecting extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Singh RM; Singh HL
    J Infect Dev Ctries; 2014 Apr; 8(4):408-15. PubMed ID: 24727505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone.
    MacGowan AP; Wootton M; Hedges AJ; Bowker KE; Holt HA; Reeves DS
    J Antimicrob Chemother; 1996 Aug; 38(2):193-203. PubMed ID: 8877533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
    Kumari N; Mohapatra TM; Rai A; Bhattacharya SK
    Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
    Yasmin F; Akhtar N; Hameed A
    Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
    Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL
    J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
    Toh HS; Chuang YC; Huang CC; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Ko WC; Yu KW; Liu YC; Chen YS; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S18-23. PubMed ID: 22749054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.